FDA grants tentative approval to Mylan's HIV/AIDS drug: 3 things to know

The Food and Drug Administration awarded tentative approval to Mylan's antiretroviral drug TLE400.

Here are three things to know.

1. The FDA approved the drug under the President's Emergency Plan for AIDS Relief, a federal initiative to combat the global HIV/AIDS epidemic.

2. TLE400 will be used as a first-line treatment regimen for HIV/AIDS patients in developing countries.

3. The World Health Organization recommended the drug as an alternative first-line treatment for HIV-positive adults in 2016.

More articles on supply chain:

96% of older Americans want Medicare to negotiate drug costs: 4 survey findings
FDA granted 99% of applications for access to unapproved drugs in FY 2016
FDA warns of safety risks with Abbott's dissolving stent: 5 takeaways

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers